Anti-BCMA Chimeric Antigen Receptors with Fully Human Heavy-chain-only Antigen Recognition Domains

Overview

Journal Nat Commun

Specialty Biology

Date 2020 Jan 17

PMID 31941907

Citations 65

Authors

Norris Lam

Nathan D Trinklein

Benjamin Buelow

George H Patterson

Namrata Ojha

James N Kochenderfer

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptor (CAR)-expressing T cells targeting B-cell maturation antigen (BCMA) have activity against multiple myeloma, but improvements in anti-BCMA CARs are needed. We demonstrated recipient anti-CAR T-cell responses against a murine single-chain variable fragment (scFv) used clinically in anti-BCMA CARs. To bypass potential anti-CAR immunogenicity and to reduce CAR binding domain size, here we designed CARs with antigen-recognition domains consisting of only a fully human heavy-chain variable domain without a light-chain domain. A CAR designated FHVH33-CD8BBZ contains a fully human heavy-chain variable domain (FHVH) plus 4-1BB and CD3ζ domains. T cells expressing FHVH33-CD8BBZ exhibit similar cytokine release, degranulation, and mouse tumor eradication as a CAR that is identical except for substitution of a scFv for FHVH33. Inclusion of 4-1BB is critical for reducing activation-induced cell death and promoting survival of T cells expressing FHVH33-containing CARs. Our results indicate that heavy-chain-only anti-BCMA CARs are suitable for evaluation in a clinical trial.

Citing Articles

CAR-T cells in the treatment of multiple myeloma: an encouraging cell therapy.

Yu T, Jiao J, Wu M Front Immunol. 2025; 16:1499590.

PMID: 40078993 PMC: 11897482. DOI: 10.3389/fimmu.2025.1499590.

Targeting BCMA in multiple myeloma: designs, challenges, and future directions.

Hu Y, Xie Y, Wang X, Yang L, Geng H, Yi Z Cancer Immunol Immunother. 2025; 74(3):77.

PMID: 39891674 PMC: 11787132. DOI: 10.1007/s00262-024-03913-0.

Clinical updates of B‑cell maturation antigen‑targeted therapy in multiple myeloma (MM) and relapsed/refractory MM (Review).

Xing R, Wang M, Wang L, Pan M, Wang Y, Zhou H Int J Mol Med. 2024; 55(2).

PMID: 39670288 PMC: 11670867. DOI: 10.3892/ijmm.2024.5468.

Chimeric antigen receptor T-cell therapy in autoimmune diseases.

Liu J, Zhao Y, Zhao H Front Immunol. 2024; 15:1492552.

PMID: 39628482 PMC: 11611814. DOI: 10.3389/fimmu.2024.1492552.

CAR T-cell therapy to treat multiple myeloma: current state and future directions.

Reddy S, Hosoya H, Mikkilineni L Cancer Metastasis Rev. 2024; 44(1):14.

PMID: 39625587 DOI: 10.1007/s10555-024-10219-1.

References

HAMERS-CASTERMAN C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa E . Naturally occurring antibodies devoid of light chains. Nature. 1993; 363(6428):446-8. DOI: 10.1038/363446a0. View

Laabi Y, Gras M, Brouet J, Berger R, Larsen C, Tsapis A . The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res. 1994; 22(7):1147-54. PMC: 523635. DOI: 10.1093/nar/22.7.1147. View

Holliger P, Hudson P . Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005; 23(9):1126-36. DOI: 10.1038/nbt1142. View

Clarke S, Ma B, Trinklein N, Schellenberger U, Osborn M, Ouisse L . Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies. Front Immunol. 2019; 9:3037. PMC: 6330309. DOI: 10.3389/fimmu.2018.03037. View

Salem D, Maric I, Yuan C, Liewehr D, Venzon D, Kochenderfer J . Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma. Leuk Res. 2018; 71:106-111. PMC: 8063571. DOI: 10.1016/j.leukres.2018.07.015. View

Sommermeyer D, Hill T, Shamah S, Salter A, Chen Y, Mohler K . Fully human CD19-specific chimeric antigen receptors for T-cell therapy. Leukemia. 2017; 31(10):2191-2199. PMC: 5608623. DOI: 10.1038/leu.2017.57. View

Li N, Fu H, Hewitt S, Dimitrov D, Ho M . Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma. Proc Natl Acad Sci U S A. 2017; 114(32):E6623-E6631. PMC: 5559039. DOI: 10.1073/pnas.1706055114. View

Carpenter R, Evbuomwan M, Pittaluga S, Rose J, Raffeld M, Yang S . B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013; 19(8):2048-60. PMC: 3630268. DOI: 10.1158/1078-0432.CCR-12-2422. View

Hughes M, Yu Y, Dudley M, Zheng Z, Robbins P, Li Y . Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther. 2005; 16(4):457-72. PMC: 1476695. DOI: 10.1089/hum.2005.16.457. View

10.

Schneider D, Xiong Y, Wu D, Nlle V, Schmitz S, Haso W . A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. J Immunother Cancer. 2017; 5:42. PMC: 5433150. DOI: 10.1186/s40425-017-0246-1. View

11.

Sadelain M, Brentjens R, Riviere I . The basic principles of chimeric antigen receptor design. Cancer Discov. 2013; 3(4):388-98. PMC: 3667586. DOI: 10.1158/2159-8290.CD-12-0548. View

12.

Boyiadzis M, Bishop M, Abonour R, Anderson K, Ansell S, Avigan D . The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90. PMC: 5168808. DOI: 10.1186/s40425-016-0188-z. View

13.

Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015; 5(12):1282-95. PMC: 4670800. DOI: 10.1158/2159-8290.CD-15-1020. View

14.

Goldschmidt H, Ashcroft J, Szabo Z, Garderet L . Navigating the treatment landscape in multiple myeloma: which combinations to use and when?. Ann Hematol. 2018; 98(1):1-18. PMC: 6334731. DOI: 10.1007/s00277-018-3546-8. View

15.

Alabanza L, Pegues M, Geldres C, Shi V, Wiltzius J, Sievers S . Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains. Mol Ther. 2017; 25(11):2452-2465. PMC: 5675490. DOI: 10.1016/j.ymthe.2017.07.013. View

16.

Kriegsmann K, Kriegsmann M, Cremer M, Schmitt M, Dreger P, Goldschmidt H . Cell-based immunotherapy approaches for multiple myeloma. Br J Cancer. 2018; 120(1):38-44. PMC: 6325139. DOI: 10.1038/s41416-018-0346-9. View

17.

Long A, Haso W, Shern J, Wanhainen K, Murgai M, Ingaramo M . 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015; 21(6):581-90. PMC: 4458184. DOI: 10.1038/nm.3838. View

18.

Sanchez E, Li M, Kitto A, Li J, Wang C, Kirk D . Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012; 158(6):727-38. DOI: 10.1111/j.1365-2141.2012.09241.x. View

19.

Ruella M, Barrett D, Kenderian S, Shestova O, Hofmann T, Perazzelli J . Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016; 126(10):3814-3826. PMC: 5096828. DOI: 10.1172/JCI87366. View

20.

Kochenderfer J, Feldman S, Zhao Y, Xu H, Black M, Morgan R . Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009; 32(7):689-702. PMC: 2747302. DOI: 10.1097/CJI.0b013e3181ac6138. View